Tenax Therapeutics Provides Clinical Development Update
Tenax Therapeutics, Inc. (TENX)
Last tenax therapeutics, inc. earnings: 11/14 04:31 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.tenaxthera.com
Company Research
Source: Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided an update on its on-going clinical trial of levosimendan.Clinical Development UpdateTenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study is also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF). There are currently 12 activated sites, with an additional three sites expected to be activated over the next few weeks, which we believe will be sufficient to fully enroll the trial. Eight patients, up from three at the end of June, are currently enrolled out of the targeted 36 patients. Three of the eight p
Show less
Read more
Impact Snapshot
Event Time:
TENX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TENX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TENX alerts
High impacting Tenax Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TENX
News
- Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceGlobeNewswire
- Tenax Therapeutics, Inc. (NASDAQ: TENX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $16.00 price target on the stock.MarketBeat
- Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $16.00 price target on the stock.MarketBeat
TENX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- TENX's page on the SEC website